Bronchiectasis

Lung Diseases

Bronchiectasis

What is Bronchiectasis?

Bronchiectasis is a pulmonary condition in which damage to the airways causes them to widen and become scarred. The lung disease causes your airways to slowly lose their ability to clear out mucus. As a result, the mucus continues to build up creating a mucus blockage, which allows bacteria to continually grow. This often results in repeated lung infections. The blockage and accompanying infections cause inflammation, which lead to weakened air passages and difficulty breathing. Over time, the airways will lose their ability to move air in and out. This can prevent a sufficient amount of oxygen from reaching vital life-sustaining organs.

 

Who’s Affected?

Sex

Bronchiectasis is a disease that doesn’t discriminate. Both women and men can develop bronchiectasis, but women have a higher risk of development. Overall, two-thirds of individuals with bronchiectasis are women.

Age

Non-congenital bronchiectasis typically affects adults and older children. It is significantly more common than the congenital type, which only affects children.

If you would like to find out more about our available treatment options, please contact one of our patient care coordinators today at (800) 729-3065 to schedule a free consultation.

albert

Albert C. | Trumansburgh, NY | Interstitial Lung Disease and Bronchiectasis

“It takes me less time and oxygen to tend to my horse farm.”

Related Posts

  • Pulmonary fibrosis causes scar tissue to form in the lungs’ air sacs, making it more difficult for the lungs to deliver oxygen to the bloodstream. A type of interstitial lung ... Read more
  • Chronic obstructive pulmonary disease (COPD), a chronic lung disease characterized by shortness of breath, wheezing, chest tightness and constant coughing, can feel like a death sentence to many. For those ... Read more

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.